Trial Profile
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2019 Since June 2018, 7 patients have been enrolled in a single center and 13 additional centers are expected to open before the end of 2019 as per trial design presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 14 Dec 2019 Trial design presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 06 May 2019 Status changed from not yet recruiting to recruiting.